Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Department of Surgery, Division of Surgical Oncology, The Ohio State University, N924 Doan Hall, 410 W. 10th Ave, Columbus, OH, 43210, USA.
J Hematol Oncol. 2021 Jan 13;14(1):15. doi: 10.1186/s13045-020-00999-8.
Bruton's tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in this process. Understanding the potential mechanism of action of BTK inhibition in SARS-CoV-2 is clearly of importance to determine how acalabrutinib, ibrutinib and possibly other BTK inhibitors may provide protection against lung injury.
布鲁顿酪氨酸激酶（BTK）抑制剂是用于癌症治疗的药物，现正被重新用于治疗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）（COVID-19）。最近发现，BTK 抑制剂阿卡替尼和依鲁替尼可预防一小部分感染 SARS-CoV-2 的患者发生肺部损伤。COVID-19 患者发生严重肺部疾病时循环中发现的高水平促炎细胞因子表明，先天免疫系统在此过程中发挥作用。明确 BTK 抑制在 SARS-CoV-2 中的潜在作用机制对于确定阿卡替尼、依鲁替尼和可能的其他 BTK 抑制剂如何提供肺部损伤保护作用非常重要。
